



# Identikit delle persone con co-infezione HIV/HCV in Italia

---


**Antonella d'Arminio Monforte**  
**Dipartimento di Scienze della Salute**  
**Università di Milano**  
**ASST Santi Paolo e Carlo, Milano**

# Prevalenza HCV in Italia $\approx 3\%$

- Stima infetti:  $\approx 1.500.000$  italiani
- Stima eleggibili alla tx:  $\approx 300.000$  soggetti
- Stima di soggetti in urgent need to tx:  
 $\approx 30.000$  in 18 mesi

***Dati AIFA***

## Anti-HCV antibody prevalence in different EuroSIDA regions



18,786 HIV-positive  
16,371 tested for anti-HCV  
5,298 anti-HCV positive  
32.4% (95% CI 31.6 -33.1)  
3,645 (68.8%) tested for HCV-RNA  
2,571 HCV-RNA positive  
70.5% (95% CI 69.1 -72.0)


- South: 28.8%
- West: 20.1%
- North: 17.3%
- East Central: 34.0%
- East: 57.7%
- Argentina: 20.6%

# Incidence of anti-HCV seroconversion according to mode of HIV transmission in ICONA COHORT


Mode of HIV transmission	N of anti HCV seroconv.	PYFU	Incidence Rate	95%CI
Heterosexuals	73	9735	0,7	0.6-0.9
IDU	41	466	8,8	6.5-11.9
MSM	85	6020	1,4	1.1-1.7
Other/unknown	8	1157	0,7	0.3-1.4




## HBsAg and HCVAb positivity in 13.229 patients enrolled in ICONA




## HBsAg and HCVAb positivity according to gender in 13.229 patients from ICONA



## HCVAb status according to mode of HIV transmission in ICONA




## HCVAb pos according to gender and mode of HIV transmission in 13.229 ICONA patients






## Median age at first positive HCVAb/HBsAg test according to gender


*25<sup>th</sup>-75<sup>th</sup> percentile as error bars*



## Proportion of patients with an HCVAb positive test within 1 year from enrolment, according to calendar year of enrolment




## Proportion of patients with an HCVAb positive test within 1 year from enrolment, according to calendar year of enrolment and gender




## Mode of HIV transmission according to calendar period of enrollment


for 2016, first 6 months




## Prevalence of HCV-RNA pos in 1672 HCVAb pos patients tested for HCV-RNA in ICONA



## Proportion of HCV genotypes for 1.418 HCV-RNA+ patients in ICONA




■ 1 ■ 2 ■ 3 ■ 4




■ 1 ■ 1a ■ 1a/1b ■ 1b ■ 1c

# HCV genotypes according to age at HIV diagnosis in ICONA patients




# HCV genotypes according to mode of HIV transmission in ICONA patients





## Proportion of HCV-RNA positive patients starting any anti-HCV treatment in ICONA till December 2012 (n=1429)






Patients  
enrolled in ICONA  
cohort  
HCV-RNA pos  
at/later than Dec  
2013  
(n=858)

HEPAICONA  
Patients:  
-HIV/HCV coinfectd  
-HCV RNA pos  
-DAA naives  
(n=1595)

ICONA/HEPAICONA  
Patients:  
HCV-RNA pos at/later  
than Jan 2013  
(n=2453)

## Demographic characteristics of 2453 HepalCONA+ICONA Patients







**HEPA** Hepatitis IcoNa Cohort  
**icona**




**Fondazione IcoNa**  
ITALIAN COHORT NAIVE ANTIRETROVIRALS




## Proportion of HCV genotypes in 2253 IcoNa/HepalcoNa patients




## Previous anti-HCV (failing) treatment at Jan 2013 in Icona/Hepalcona



## FIB4 strata in ICona/HepalCONA patients at start of any anti-HCV treatment (n=766)



## Prevalence of start of any anti-HCV treatment according to last FIB4 value in Icona/Hepalcona patients






**HEPA** Hepatitis Icona Cohort  
**icona**



**Fondazione Icona**  
ITALIAN COHORT NAIVE ANTIRETROVIRALS



## Outcome of DAA regimens started in Icona/Hepaicona




\* Date of End of Treatment (EOT) < 01/04/2016  
or Date of start < 01/10/2015


*Jun 2016 Report*




## Proportion of hepatic decompensation occurred at any time in patients with last Fib4>3,25 in Icona/Hepalcona (n=419)





## Proportion of individual events of hepatic decompensation occurred at any time in patients with last Fib4>3,25 in Icona/Hepalcona




## Outcome of IcoNa and HepalcoNa patients with decompensated cirrhosis starting a DAA (n=84)



# HIV/HCV Co-infected Patients in Milan prisons (S.Vittore, Opera and Bollate) – 2016






## HIV/HCV Co-infected Patients in Milan prisons: HCV Genotypes distribution in 32 patients



■ HCV Genotype 1 ■ HCV Genotype 2 ■ HCV Genotype 3 ■ HCV Genotype 4

# HIV/HCV pos DAAs Treated Patients in Milan prisons (S.Vittore, Opera and Bollate)



■ G. 1 ■ G. 3 ■ G. 4

## **Identikit delle persone con co-infezione HIV/HCV in Italia: conclusioni**

---

- ✓ Nei soggetti HIV pos infezione da HCV prevalentemente correlata alla tossicodipendenza
- ✓ Genotipo 1a e genotipo 3 i più diffusi
- ✓ Ridotta prevalenza di HCV nei soggetti con nuova diagnosi di HIV
- ✓ Dati sovrapponibili nelle carceri milanesi
- ✓ Successo della terapia, analogamente agli HIV negativi, e anche in regime di contenzione